{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:35:44Z","timestamp":1760297744811},"reference-count":76,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,8,18]],"date-time":"2006-08-18T00:00:00Z","timestamp":1155859200000},"content-version":"vor","delay-in-days":6804,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Surgical Oncology"],"published-print":{"date-parts":[[1988,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The most active single agents in soft\u2010tissue sarcomas are doxorubicin (Adriamycin) and ifosfamide, with response rates of 20\u201035%. Dacarba\u2010zine (DTIC) has a response rate of 16%. A randomized trial of 5 g\/m<jats:sup>2<\/jats:sup> of ifosfamide versus 1.5 g\/m<jats:sup>2<\/jats:sup> of cyclophosphamide noted a higher response rate for ifosfamide with less myelosuppression. Both randomized studies of doxorubicin with or without DTIC documented an increased response rate for the combination. In contrast, three randomized trials of doxorub\u2010icin\u2010based regimens with and without cyclophosphamide have failed to detect an advantage for the addition of cyclophosphamide. Thus, the most active combination for soft\u2010tissue sarcomas is doxorubicin and DTIC. The role of the addition of ifosfamide is currently under evaluation.<\/jats:p>","DOI":"10.1002\/ssu.2980040111","type":"journal-article","created":{"date-parts":[[2007,2,22]],"date-time":"2007-02-22T06:25:58Z","timestamp":1172125558000},"page":"53-58","source":"Crossref","is-referenced-by-count":20,"title":["Chemotherapy of advanced soft\u2010tissue sarcomas"],"prefix":"10.1002","volume":"4","author":[{"given":"Karen H.","family":"Antman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony D.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,8,18]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.36.1.9"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197809)42:3<1152::AID-CNCR2820420319>3.0.CO;2-L"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(81)90009-2"},{"key":"e_1_2_1_5_2","first-page":"84","article-title":"The value of radiation therapy in uterine sarcoma","volume":"45","author":"Gilbert HA","year":"1975","journal-title":"Obstet Gynecol"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(66)90386-3"},{"key":"e_1_2_1_7_2","first-page":"1192","article-title":"Thoracic soft\u2010tissue sarcoma in Vietnam veterans exposed to agent orange","volume":"306","author":"Sarma PR","year":"1982","journal-title":"N Engl J Med"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.6342136"},{"key":"e_1_2_1_9_2","first-page":"247","article-title":"An overview of studies in adriamycin (NSC\u2010123127) in the United States","volume":"6","author":"Blum RH","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197307)32:1<1::AID-CNCR2820320101>3.0.CO;2-X"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000225192"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821215)50:12<2757::AID-CNCR2820501211>3.0.CO;2-J"},{"key":"e_1_2_1_13_2","first-page":"231","article-title":"Randomized comparison of adriamycin regimens for treatment of metastatic soft tissue sarcomas","volume":"1983","author":"Borden EC","year":"1902","journal-title":"Proc ASCO"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930110406"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-96-2-133"},{"key":"e_1_2_1_17_2","first-page":"194","article-title":"High dose methotrex\u2010ate (HDMTX) with citrovorum factor rescue (CFR) in the treatment of radiation\u2010induced sarcomas","volume":"1983","author":"Rosen G","year":"1981","journal-title":"Proc AACR"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(80)90105-9"},{"key":"e_1_2_1_19_2","first-page":"409","article-title":"High dose methotrexate with leucovorin rescue plus vincristine in advanced sarcoma: A southwest oncology group study","volume":"68","author":"Vaughn C","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197904)43:4<1177::AID-CNCR2820430403>3.0.CO;2-R"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19800915)46:6<1345::AID-CNCR2820460608>3.0.CO;2-R"},{"key":"e_1_2_1_22_2","first-page":"233","article-title":"\u201cSingle\u201d\u2010agent activity of high\u2010dose methotrexate therapy with citrovorum factor rescue","volume":"62","author":"Von Hoff DD","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_23_2","first-page":"1295","article-title":"Phase II clinical trail with high\u2010dose methotrexate therapy and citrovorum factor rescue","volume":"62","author":"Isacoff WH","year":"1978","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_24_2","first-page":"471","article-title":"Phase II study of methotrexate (NSC 740) in solid tumors","volume":"51","author":"Andrews N","year":"1967","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_25_2","first-page":"683","volume-title":"Chemotherapy of sarcoma\u2014a comparison of three regimens","author":"Subramanian S","year":"1978"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00170765"},{"key":"e_1_2_1_27_2","first-page":"935","article-title":"A clinical study of 5\u2010fluorour\u2010acil","volume":"19","author":"Gold G","year":"1959","journal-title":"Cancer Res"},{"key":"e_1_2_1_28_2","unstructured":"GolbeyR LiMC KaufmanRF:Actinomycin in the treatment of soft part sarcomas. James Ewing Soc Sci Prog (abstr) 1968."},{"key":"e_1_2_1_29_2","first-page":"497","article-title":"Effect of vincristine (NSC\u201067574) on malignant solid tumors in children","volume":"52","author":"Selawry OS","year":"1968","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_30_2","first-page":"249","article-title":"Low doses of vincristine (NSC\u201067574) for malignant disease","volume":"53","author":"Korbitz BC","year":"1969","journal-title":"Cancer Chemo\u2010ther Rep"},{"key":"e_1_2_1_31_2","first-page":"1231","article-title":"Therapeutic trials with VP\u201016 and VM26","volume":"63","author":"Radice PA","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_32_2","first-page":"373","article-title":"Epipodophyllotoxin therapy of childhood neoplasia. A comparative phase II analysis of VM\u201026 and VP 16\u2010213","volume":"19","author":"Bleyer WA","year":"1978","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(79)90032-X"},{"key":"e_1_2_1_34_2","first-page":"2071","article-title":"Cis\u2010dichlorodia\u2010mineplatinum (II) in metastatic soft tissue sarcomas","volume":"63","author":"Karakousis CP","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_35_2","first-page":"2027","article-title":"Cis\u2010dichlorodia\u2010mineplatinum (II) in advanced soft tissue and bony sarcomas","volume":"63","author":"Samson MK","year":"1979","journal-title":"A Southwest Oncology Group Study. Cancer Treat Rep"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1987.5.4.618"},{"key":"e_1_2_1_37_2","first-page":"120","article-title":"A prelusive clinical trial of cyclophos\u2010phamide","volume":"8","author":"Bergsagel DE","year":"1960","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_38_2","first-page":"1","article-title":"Preliminary evaluation of the effect of cyclophosphamide on the course of human neoplasms","volume":"7","author":"Korst DR","year":"1960","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_39_2","first-page":"1943","volume-title":"Cancer, Principals & Practice of Oncology","author":"Rosenberg SA"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(83)80025-5"},{"key":"e_1_2_1_41_2","first-page":"377","article-title":"Clinical studies with uromi\u2010texan\u2014an antidote against urotoxicity of holoxan. Preliminary results","volume":"30","author":"Czownicki Z","year":"1980","journal-title":"Nowotwory"},{"key":"e_1_2_1_42_2","first-page":"109","volume-title":"Proc Inter Holoxan Symposium","author":"Czownicki A","year":"1977"},{"key":"e_1_2_1_43_2","unstructured":"ScheulenM NiederleNorbert SeeberS: Results of a clinical phase II study on the use of ifosfamide in refractory malignant diseases. Comparison of the uroprotective effect of uromitexan and forced diuresis with alkalization of the urine. InNew Experience With the Oxazaphosphorine With Special Reference to the Uroprotector Uromitexan. Burkert H Nagel GA (eds):1980 p40."},{"key":"e_1_2_1_44_2","first-page":"136","article-title":"Treatment of recurrent sarcomas with ifosfamide (IF)","volume":"4","author":"Magrath IT","year":"1985","journal-title":"ASCO"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1070478"},{"key":"e_1_2_1_46_2","first-page":"499","article-title":"Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma","volume":"69","author":"Antman K","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(83)80023-1"},{"key":"e_1_2_1_48_2","first-page":"234","article-title":"Phase II trial of ifosfamide (IFOS) with Mesna in patients with pediatrie malignant solid tumors","volume":"4","author":"Pratt C","year":"1985","journal-title":"ASCO"},{"key":"e_1_2_1_49_2","first-page":"81","volume-title":"Beitrage zur Onkologie","author":"Wellens W","year":"1980"},{"key":"e_1_2_1_50_2","first-page":"159","article-title":"Therapie pro\u2010gredienter Sarkome mit Etososid und Ifosfamide","volume":"4","author":"Wellens W","year":"1981","journal-title":"Etoposide Symposium, Aktuelle Onkologie, Zuckschwerdt Munchen."},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.3109\/08880018409141708"},{"key":"e_1_2_1_52_2","first-page":"143","article-title":"Cyclophosphamide versus Ifosfamide: A randomized phase II trial in adult soft tissue sarcoma. Preliminary report of EORTC soft tissue and bone sarcomas group","volume":"4","author":"Bramwell V","year":"1985","journal-title":"ASCO"},{"key":"e_1_2_1_53_2","first-page":"271","article-title":"Adriamycin (NSC\u2010123127) used alone and in combination for soft tissue and bony sarcomas","volume":"6","author":"Gottlieb JA","year":"1975","journal-title":"Cancer Chemother Rep"},{"key":"e_1_2_1_54_2","first-page":"256","article-title":"CYVADIC vs CYVADACT\u2010a randomized trial of cyclophosphamide (CY), vincristine (V), and adriamycin (A) plus either dacarbazine (DIC) or actinomycin\u2010D (DACT) in metastatic sarcomas","volume":"17","author":"Benjamin RS","year":"1976","journal-title":"Proc Am Assoc Cancer Res Am Soc Clin Oncol"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830815)52:4<626::AID-CNCR2820520409>3.0.CO;2-E"},{"key":"e_1_2_1_56_2","first-page":"142","article-title":"Leiomyosarcoma: The Eastern Cooperative Oncology Group experience with 222 patients","volume":"24","author":"Lerner H","year":"1983","journal-title":"Proc Am Assoc Cancer Res"},{"key":"e_1_2_1_57_2","unstructured":"LarryBaker Personal communication."},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19801015)46:8<1722::AID-CNCR2820460803>3.0.CO;2-M"},{"key":"e_1_2_1_59_2","first-page":"683","volume-title":"Chemotherapy of sarcoma, A comparison of three regimens","author":"Subramanian S","year":"1978"},{"key":"e_1_2_1_60_2","first-page":"352","article-title":"Survival and relapse patterns of complete responders in adults with advanced soft tissue sarcomas (ASTS), Proc","volume":"20","author":"Yap BS","year":"1979","journal-title":"Am Assoc Cancer Res ASCO"},{"key":"e_1_2_1_61_2","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/1097-0142(19810515)47:10<2422::AID-CNCR2820471017>3.0.CO;2-Y","article-title":"Protected Environment\u2014Prophylactic Antibiotic program for malignant sarcoma: Randomized trial during remission induction chemotherapy","volume":"47","author":"Bodey GP","journal-title":"Cancer"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19840501)53:9<1825::AID-CNCR2820530904>3.0.CO;2-Z"},{"key":"e_1_2_1_63_2","first-page":"236","article-title":"Effectiveness of combination of ifosfamide, vincristine and actinomycine D in inducing remission in rhabdomysarcoma in children. For the RMS groups of the International Society of Pediatrie Oncology (S1OP)","volume":"4","author":"Otten J","year":"1985","journal-title":"ASCO"},{"key":"e_1_2_1_64_2","volume-title":"Doxorubicin (DOX), ifosfamide (IFF), and DTIC with mesna uroprotection for advanced untreated sarcoma","author":"Elias AD","year":"1987"},{"key":"e_1_2_1_65_2","first-page":"827","article-title":"Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: A phase I study","volume":"70","author":"Elias A","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_66_2","first-page":"145","article-title":"Adriamycin (A) and ifosfamide (I), a new effective combination in advanced soft tissue sarcoma; preliminary report of a phase II study of the EORTC soft tissue and bone sarcoma group","volume":"5","author":"Schutte J","year":"1986","journal-title":"Proc ASCO"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197212)30:6<1632::AID-CNCR2820300632>3.0.CO;2-S"},{"key":"e_1_2_1_68_2","volume-title":"Cancer Chemotherapy Fundamental Concepts and Recent Advances, 19th Annual Clinical Conference in Cancer, 1974, M.D. Anderson Hospital","author":"Gottlieb JA","year":"1975"},{"key":"e_1_2_1_69_2","first-page":"1385","article-title":"A comparative clinical trial evaluating the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl\u2010CCNU, in advanced sarcomas","volume":"60","author":"Creagan ET","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_70_2","first-page":"93","article-title":"Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas","volume":"64","author":"Yap B","year":"1980","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_71_2","first-page":"346","volume-title":"Re\u2010evaluation of the CYVADIC regimen for metastatic soft tissue sarcoma","author":"Pinedo HM","year":"1979"},{"key":"e_1_2_1_72_2","first-page":"537","volume-title":"Pathology of Soft Tumors","author":"Shiu MH","year":"1979"},{"key":"e_1_2_1_73_2","first-page":"289","article-title":"Combination chemotherapy with adriamyin, cyclophosphamide and methotrexate in metastatic sarcomas","volume":"18","author":"Lowenbraun S","year":"1977","journal-title":"ASCO (abstr)"},{"key":"e_1_2_1_74_2","first-page":"446","article-title":"Methyl CCNU and adriamycin for patients with metastatic sarcomas","volume":"46","author":"Rivkin SE","year":"1980","journal-title":"A Southwest Oncology Group Study. Cancer"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt1976205605"},{"key":"e_1_2_1_76_2","first-page":"742","article-title":"Combined adriamycin, vincristine, and methotrexate","volume":"77","author":"Kaufman JH","year":"1977","journal-title":"NY State J Med"},{"key":"e_1_2_1_77_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197002)25:2<324::AID-CNCR2820250208>3.0.CO;2-F"}],"container-title":["Seminars in Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fssu.2980040111","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ssu.2980040111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T10:47:36Z","timestamp":1697971656000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ssu.2980040111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1988,1]]}},"alternative-id":["10.1002\/ssu.2980040111"],"URL":"https:\/\/doi.org\/10.1002\/ssu.2980040111","archive":["Portico"],"relation":{},"ISSN":["8756-0437","1098-2388"],"issn-type":[{"value":"8756-0437","type":"print"},{"value":"1098-2388","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,1]]}}}